Publications by authors named "H Akamine"
International consensus guidance and Japanese clinical guidelines for myasthenia gravis (MG) recommend achieving minimal manifestations or better status (MM-or-better) as the severity component of the treatment goal. However, the subjective nature of determining MM can result in ambiguity regarding this category in clinical practice and clinical trials. This study analyzed severity metrics in a large number of MG patients to propose criteria for MM-or-better.
View Article and Find Full Text PDFArticle Synopsis
- * Research showed that serum CAF levels are significantly higher in patients with acetylcholine receptor antibody-positive myasthenia gravis (AChR-MG) compared to healthy individuals, but not in those with muscle-specific kinase antibody-positive myasthenia gravis.
- * In AChR-MG patients, higher CAF levels were linked to better daily living activities post-treatment, suggesting that elevated CAF may be beneficial for NMJ regeneration and could indicate protective responses against the disease.
Article Synopsis
- The study aimed to evaluate the safety of statins in patients with myasthenia gravis (MG), particularly focusing on muscle-related symptoms and potential worsening of myasthenic symptoms.
- Among 1710 MG patients reviewed, only 2% experienced statin intolerance, and 1.5% showed myasthenic worsening, with common issues like ptosis.
- The findings suggest that while statin-associated myasthenic worsening is rare and generally mild, symptoms improve quickly after stopping the medication, indicating statins can be safely used in MG patients with some caution.
Article Synopsis
- CAR T cell therapy has shown success in treating blood cancers but struggles with solid tumors like non-small cell lung cancer (NSCLC) due to a lack of specific cell surface targets.
- Researchers identified that CD98 heavy chain protein is overexpressed in NSCLC cells and could serve as a target for CAR T cells.
- A specific monoclonal antibody called R8H283, which reacts selectively with NSCLC cells without impacting normal tissues, led to the development of CAR T cells that demonstrated significant anti-tumor effects in model studies.